← Back to patent-cliff list
Samarium (153Sm) lexidronam pentasodium
Tier C — Watch / tradeSamarium (153Sm) lexidronam pentasodium
-
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Reactive oxygen species
Brand：Quadramet
Indications (approved)：Pain
Regional status
US
Withdrawn
EU
Approved
1998-02-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Samarium (153Sm) lexidronam pentasodium?
Approved indications include: Pain.
When does the Samarium (153Sm) lexidronam pentasodium patent expire?
No public expiry year is available for Samarium (153Sm) lexidronam pentasodium yet; this page updates once verified.
How do I get a quote for Samarium (153Sm) lexidronam pentasodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27